Abstract：【Objective】To investigate the levels of serum neutrophil gelatinase associated lipid carrier protein (NGAL),cysteine protease inhibitor C (cys C) and urinary renal injury factor 1 (KIM-1) in patients with cirrhosis complicated with acute renal injury (AKI) and analyze the risk factors of AKI. 【Methods】A total of 184 patients with liver cirrhosis were divided into the AKI group (n=27) and the non AKI group (n=157) according to whether they were complicated with AKI. The difference between the two groups of patients' basic information and the detection level of relevant laboratory indicators [including hemoglobin (Hb),serum albumin (ALB),white blood cells (WBC),platelet count (PLT),serum alanine aminotransferase (ALT),aspartate aminotransferase (AST),prothrombin activity (PTA),NGAL,cys C,and urinary KIM-1] were collected and compared. The serum NGAL cys C and urinary KIM-1 levels were used to predict the value of AKI in patients with liver cirrhosis. Finally,the different information between the two groups was included in the multivariate logistic regression analysis,and the quantitative assignment was performed to identify the risk factors of AKI in patients with liver cirrhosis. 【Results】There was no significant difference between the two groups in terms of age,sex,body mass index,hypertension,smoking history,classification of liver cirrhosis,etiology of liver cirrhosis,ascites,Hb,ALB,WBC,PLT,PTA,ALT and AST levels (P>0.05).The proportion of patients with AKI combined with diabetes and infection,and the levels of serum NGAL,serum cys C and urinary KIM-1 were significantly higher than those in non AKI group (P<0.05). ROC analysis showed that serum NGAL,cys C and urinary KIM-1 were used to predict AKI in patients with liver cirrhosis. The areas under the curve were 0.854,0.835 and 0.834,respectively,(all P<0.05). Multivariate logistic regression analysis showed that diabetes,infection,serum NGAL,cys C and urinary KIM-1 were independent influencing factors of AKI in patients with liver cirrhosis (P<0.05). 【Conclusion】Serum NGAL,cys C and urinary KIM-1 levels were significantly increased in patients with cirrhosis complicated with AKI,which can be used as sensitive indicators for early prediction of cirrhosis complicated with AKI.
邓向海, 黄钰莹, 黄宁, 王涛. 肝硬化并发急性肾损伤患者血清NGAL、cys C及尿KIM-1的表达及其意义[J]. 医学临床研究, 2022, 39(8): 1235-1238.
DENG Xiang-hai, HUANG Yu-ying, HUANG Ning, et al. Expression and Significance of Serum NGAL,cys C and Urinary KIM-1 in Patients with Liver Cirrhosis Complicated with Acute Renal Injury. JOURNAL OF CLINICAL RESEARCH, 2022, 39(8): 1235-1238.
[1] 向瑞,李振江. 中性粒细胞明胶酶相关脂质运载蛋白在AKI中的研究进展和应用评价[J].中国中西医结合肾病杂志,2020,21(1):84-86. [2] 姜洁,吕菁君,叶璐,等. 可溶性血栓调节蛋白及中性粒细胞明胶酶相关脂质运载蛋白早期预测脓毒症相关急性肾损伤的临床研究[J].中华急诊医学杂志,2020,29(4):533-540. [3] JAQUES D A,SPAHR L,BERRA G,et al. Biomarkers for acute kidney injury in decompensated cirrhosis:A prospective study[J].Nephrology,2019,24(2):170-180. [4] 刘成海,姚树坤. 肝硬化腹水的中西医结合诊疗共识意见[J].中国中西医结合杂志,2011,31(9):1171-1174. [5] 沈斐斐,陆伦根. 肝硬化急性肾损伤的诊断与管理进展[J].中华消化杂志,2018,38(2):142-144. [6] ALLEGRETTI A S,PARADA X V,ENDRES P,et al. Urinary NGAL as a diagnostic and prognostic marker for acute kidney injury in cirrhosis:a prospective study[J].Clin Transl Gas,2021,12(5):359-362. [7] HUELIN P,SOLA E,ELIA C,et al. Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis:a prospective study[J].Hepatology,2019,70(1):319-333. [8] 庞国菊,武玉晶,刘爽,等. 肝硬化继发急性肾损伤患者血清胱抑素C和中性粒细胞明胶酶相关脂质运载蛋白的水平及其诊断价值[J] .中华肝脏病杂志,2019,27(1):65-67. [9] MOGAWER M S,ELHAMID S A,ALI A Y. Novel biomarkers of acute kidney injury following living donor liver transplantation[J].Saudi J Kid Dis Transpl,2020,31(2):360-367. [10] WENG F. Comment on "Urinary NGAL as a diagnostic and prognostic marker for acute kidney injury in cirrhosis"[J].Clin Transl Gas,2021,12(7):382-388. [11] 徐曼曼,陈煜. 肝硬化合并急性肾损伤的尿液相关预测因素分析[J].临床肝胆病杂志,2018,34(10):2124-2129. [12] GROSMAN R L,HUI S G,FREEDMAN D,et al. Biomarkers of inflammation,fibrosis,and acute kidney injury in patients with heart failure with and without left ventricular assist device implantation[J].Cardiorenal Med,2019,9(2):108-116.
2022, Vol. 39 
